Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PYGB | P11216 | 2/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21947408 | 1.00 | MAPK1 (0.65) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL6942761 | 1.00 | MAPK1 (0.65) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL3296000 | 1.00 | MAPK1 (0.65) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL6944012 | 1.00 | MAPK1 (0.65) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL3295284 | 1.00 | MAPK1 (0.65) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL3295994 | 1.00 | MAPK1 (0.65) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL23478019 | 1.00 | MAPK1 (0.65) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL23848966 | 0.94 | MAPK1 (0.61) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL21415430 | 0.89 | MAPK1 (0.51) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB | |
| SCHEMBL23735602 | 0.88 | MAPK1 (0.56) | MAPK1ALDH1A1THRBSMN1; SMN2PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049300-B2 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL (FR) | 2006-05-23 | — | — | US | claimed |
| US-20040048785-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | SOCIETE L'OREAL S.A. (FR) | 2004-03-11 | — | — | US | claimed |
| WO-2002051803-A2 | NOVEL C-GLYCOSIDE DERIVATIVES AND USE THEREOF | L'OREAL (FR) | 2002-07-04 | — | — | WO | claimed |
| EP-1345919-B1 | NOVEL C-GLYCOSIDE DERIVATIVES AND USE THEREOF | OREAL (FR) | 2013-05-22 | — | — | EP | disclosed |
| US-7732414-B2 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL S.A. (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20060223763-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL S.A. (FR) | 2006-10-05 | — | — | US | disclosed |
| US-7049300-B2 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL (FR) | 2006-05-23 | — | — | US | disclosed |
| US-20040048785-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | SOCIETE L'OREAL S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
| EP-1345919-A2 | NOVEL C-GLYCOSIDE DERIVATIVES AND USE THEREOF | L'OREAL (FR) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051803-A2 | NOVEL C-GLYCOSIDE DERIVATIVES AND USE THEREOF | L'OREAL (FR) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002051828-A2 | NOVEL C-GLYCOSIDE DERIVATIVES AND USE THEREOF | L'OREAL (FR) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223763-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | CSGALNACT1, FUT6, AREG | MAPK1 2007/4885ALDH1A1 2637/4885THRB 2233/4885 |
| US-20040048785-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | CSGALNACT1, FUT6, AREG | MAPK1 2007/4885ALDH1A1 2637/4885THRB 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.